| Field | Specification |
|---|---|
| Target | |
| Alternative names | Amyloid-beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Amyloid precursor protein; Amyloid-beta precursor protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II; S-APP-alpha; S-APP-beta; Beta-secretase C-terminal fragment; Beta-CTF; Abeta42; Beta-APP42; Abeta40; Beta-APP40; Alpha-secretase C-terminal fragment; Alpha-CTF; Amyloid intracellular domain 59; AICD-59; AID (59); Gamma-CTF (59); Amyloid intracellular domain 57; AICD-57; AID (57); Gamma-CTF (57); Amyloid intracellular domain 50; AICD-50; AID (50); Gamma-CTF (50); APP; A4; AD1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human APP/C99. |
| Molecular weight | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets amyloid-beta precursor protein (gene APP) in human samples and is validated for IHC and Western blot. The predicted molecular weight is 86.9 kDa, and the supplier reports an observed band at about 99 kDa.
Amyloid-beta precursor protein (APP) is a transmembrane protein highly expressed in neurons, where it supports neurite growth, adhesion and synapse function. Sequential cleavage by β- and γ-secretases releases amyloid-β peptides, which accumulate in the plaques of Alzheimer's disease, making APP one of the most studied proteins in neurodegeneration research.
| Target | Amyloid-beta precursor protein (gene APP; UniProt P05067, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 86.9 kDa |
| Observed MW | 99 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
Samples with a confirmed band (WB): human T-47D cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human glioma tissue, human renal cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Immunogen
Synthetic peptide from the C-terminal region of human APP/C99.
Reactivity Notes
The supplier lists reactivity with human. UniProt places amyloid-beta precursor protein in the cell membrane, membrane, perikaryon and cell projection. Tissue expression noted by UniProt (human): Expressed in the brain and in cerebrospinal fluid (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
